Patients with metastatic or recurrent gastric cancer refractory to S-@-based first-line chemotherapy were randomly assigned to receive BIRIP ( irinotecan @mg/m ( @ ) plus cisplatin @mg/m ( @ ) , every @weeks ) or irinotecan alone ( irinotecan @mg/m ( @ ) , every @weeks ) .